Erasca, Inc. (ERAS) stock
ERASNasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.89−1.22 (-8.07%)
Close on Nov 17, 2026Market cap $4.86BP/E –Yield 0.00%
Erasca total assets
Total assets on the balance sheet at the end of each period.
Erasca's total assets was $435.05M at Jun 30, 2026. For fiscal 2025 it was $396.15M, down 21.2% from the year before. The highest annual figure on record is $514.91M in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $396.15M | -21.2% |
| FY2024 | Dec 31, 2024 | $502.53M | +27.1% |
| FY2023 | Dec 31, 2023 | $395.30M | -23.2% |
| FY2022 | Dec 31, 2022 | $514.91M | +2.7% |
| FY2021 | Dec 31, 2021 | $501.42M | +301.7% |
| FY2020 | Dec 31, 2020 | $124.83M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $435.05M | -2.3% |
| Q1 FY2026 | Mar 31, 2026 | $461.23M | -2.1% |
| Q4 FY2025 | Dec 31, 2025 | $396.15M | -21.2% |
| Q3 FY2025 | Sep 30, 2025 | $420.40M | -20.5% |
| Q2 FY2025 | Jun 30, 2025 | $445.39M | -15.3% |
| Q1 FY2025 | Mar 31, 2025 | $471.24M | +27.4% |
| Q4 FY2024 | Dec 31, 2024 | $502.53M | +27.1% |
| Q3 FY2024 | Sep 30, 2024 | $528.90M | +26.1% |
| Q2 FY2024 | Jun 30, 2024 | $525.74M | +19.3% |
| Q1 FY2024 | Mar 31, 2024 | $370.02M | -20.9% |
| Q4 FY2023 | Dec 31, 2023 | $395.30M | -23.2% |
| Q3 FY2023 | Sep 30, 2023 | $419.41M | -6.1% |
| Q2 FY2023 | Jun 30, 2023 | $440.66M | -0.9% |
| Q1 FY2023 | Mar 31, 2023 | $467.54M | -1.7% |
| Q4 FY2022 | Dec 31, 2022 | $514.91M | +2.7% |
| Q3 FY2022 | Sep 30, 2022 | $446.43M | -14.5% |
| Q2 FY2022 | Jun 30, 2022 | $444.82M | +111.4% |
| Q1 FY2022 | Mar 31, 2022 | $475.47M | +280.9% |
| Q4 FY2021 | Dec 31, 2021 | $501.42M | – |
| Q3 FY2021 | Sep 30, 2021 | $521.95M | – |
| Q2 FY2021 | Jun 30, 2021 | $210.38M | – |
| Q4 FY2020 | Dec 31, 2020 | $124.83M | – |
See a number that looks wrong?